[1] Salma AlDallal. Acromegaly: a challenging condition to diagnose. Int J Gen Med. 2018;11:337-343.
[2] Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on glucose metabolism. European Journal of Endocrinology. 2013;169(1):99-108.
[3] Colao A, Ferone D, Marzullo P, et al. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews. 2004; 25(1): 102-152.
[4] Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.
[5] Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic Transsphenoidal Surgery for Acromegaly: Remission Using Modern Criteria, Complications, and Predictors of Outcome. J Clin Endocrinol Metab. 2011;96(9):2732-2740.
[6] Starke RM, Raper DM, Payne SC, et al. Endoscopic vs Microsurgical Transsphenoidal Surgery for Acromegaly: Outcomes in a Concurrent Series of Patients Using Modern Criteria For Remission. J Clin Endocrinol Metab. 2013;98(8):3190-3198.
[7] Giustina A, Chanson P, Kleinberg D, et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243-248.
[8] Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2014;99(5):1825-1833.
[9] Colao A, Auriemma RS, Galdiero M, et al. Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study. The Journal of Clinical Endocrinology & Metabolism. 2009;94(10):3746-3756.
[10] Murray, R.D. and S. Melmed. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2008;93(8):2957-2968.
[11] Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875-884.
[12] Howlett TA, Willis D, Walker G, et al. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical Endocrinology. 2013;79(5):689-699.
[13] Kopchick JJ, Parkinson C, Stevens EC, et al. Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly. Endocrine Reviews. 2002;23(5):623-646.
[14] van der Lely A J, Biller B M K, Brue T, et al. Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY. The Journal of Clinical Endocrinology & Metabolism. 2012; 97(5): 1589-1597.
[15] Leonart L P, Tonin F S, Ferreira V L, et al. Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine. 2019; 63(1): 18-26.
[16] Strasburger CJ, Mattsson A, Wilton P, et al. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant. European Journal of Endocrinology. 2018;178(4):321-329.
[17] Feola Tiziana, Cozzolino Alessia, Simonelli Ilaria, et al. Pegvisomant improves glucose metabolism in acromegaly: a meta analysis of prospective interventional studies. The Journal of Clinical Endocrinology & Metabolism. 2019;jc.2018-02281.
[18] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928-d5928.
[19] Slim K, Nini E, Forestier D, et al. Methodological Index For Non-randomized Studies (MINORS): Development and Validation of A New Instrument. ANZ J. Surg. 2003;73:712-716.
[20] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
[21] Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clinical Endocrinology. 2009;71(4):549-557.
[22] Neggers SJ, van Aken MO, de Herder WW, et al. Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. The Journal of Clinical Endocrinology & Metabolism. 2008;93(10):3853-3859.
[23] Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients. The Journal of Clinical Endocrinology & Metabolism. 2011;96(8):2405-2413.
[24] Colao A, Zgliczyński W, Komorowski J, et al. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynologia Polska, 2019, 70(4): 305-312.
[25] Muhammad A, Coopmans E C, Delhanty P J D, et al. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. European Journal of Endocrinology, 2018: 269-277.
[26] van der Lely A, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. European Journal of Endocrinology. 2011;164(3):325-333.
[27] Auriemma RS, Grasso LF, Galdiero M, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. 2017;55(3):872-884.
[28] Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist. The Journal of Clinical Endocrinology & Metabolism. 2005;90(10):5627-5631.
[29] Hannon AM, Thompson CJ, Sherlock M. Diabetes in patients with acromegaly. Curr Diab Rep. 2017;17:8.
[30] Colao A, Ferone D, Marzullo P, et al. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews. 2004;25(1):102-152.
[31] Mazziotti G, Floriani I, Bonadonna S, et al. Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(5): 1500-1508.
[32] Cozzolino A, Feola T, Simonelli I, et al. Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. The Journal of Clinical Endocrinology & Metabolism. 2018; 103(6): 2089-2099.
[33] Giustina A, Mazziotti G, Maffezzoni F, et al. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014;23(12):1619-1635.
[34] Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673–680.
[35] Hansen L, Hartmann B, Bisgaard T, et al. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab. 2000;278(6):E1010–E1018.
[36] Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist Pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156(1):75–82.
[37] Drake WM, Rowles SV, Roberts ME, et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to Pegvisomant. Eur J Endocrinol. 2003;149(6):521–527.
[38] Urbani C, Sardella C, Calevro A, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169(1):99–108.
[39] Ghigo E, Biller BM, Colao A, et al. Comparison of Pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924–933.
[40] Lindberg-Larsen R, Møller N, Schmitz O, et al. The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2007;92(5):1724-1728.
[41] Marinis De Laura, Bianchi Antonio, Fusco Alessandra, et al. Long-term effects of the combination of pegvisomant with somatosatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10:227-232.
[42] Gadelha R Monica, Bronstein D Marcello, Brue Thierry, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomized, phase 3 trial. The Lancet Diabetes & Endocrinology. 2014;2(11):875-884.
[43] Gadelha MR, Wildemberg LE, Bronstein MD, et al. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100-108.
[44] Giustina A, Ambrosio MR, Beck Peccoz P, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. Journal of Endocrinological Investigation. 2014;37(10):1017-1030.
[45] Maffei P, Martini C, Pagano C, et al. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist Pegvisomant. Ann Intern Med. 2006;145(4):310–312.
[46] Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology. 2007;156(1):75-82.
[47] Neggers SJ, van Aken MO, Janssen JA, et al. Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2007;92(12):4598-4601.